Why CTMX Stock Is Soaring 54% Pre-Market Today?
Synopsis
CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.
CytomX Therapeutics, Inc. (CTMX) on Monday announced encouraging early results from its Phase 1 expansion study of varsetatug masetecan (Varseta-M) in patients with late-line metastatic colorectal cancer (CRC).
The data, as of January 16, indicated the antibody-drug conjugate is showing meaningful response rates at optimized doses.
The CTMX-2051-101 trial, launched in April 2024, enrolled 93 heavily pretreated metastatic CRC patients, with 56 evaluable for efficacy across expansion doses of 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg administered every three weeks. Confirmed response rates increased with dose; 6% at 7.2 mg/kg, 20% at 8.6 mg/kg, and 32% at 10 mg/kg.
Following the results, CytomX Therapeutics stock traded over 54% in Monday’s premarket.
Get updates to this developing story directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.